Vascular dementia 2003

Korczyn, Amos D.; Kalvach, Pavel; Bornstein, Natan

doi:10.1016/j.jns.2004.11.002

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only limited therapeutic interventions are available to reduce the incidence of VaD. Cholinesterase inhibitors, calcium channel blockers and glutamate antagonists are few classes of pharmacological agents which are being clinically explored to reduce symptomatically the impact of cognitive dysfunction associated with vascular dementia [ 12 ]. However, an agent that should improve both endothelial dysfunction and associated dementia still need to be explored.…”

Section: Introductionmentioning

confidence: 99%

Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats

et al. 2008

View full text Add to dashboard Cite

Background: Statins, HMG-CoA reductase inhibitors, are widely prescribed drugs for dyslipidemias. Recent studies have indicated number of cholesterol independent actions of statins including their beneficial effects on vascular endothelial dysfunction and memory deficits associated with dementia of Alzheimer's type. However the potential of statins in dementia of vascular origin still remains to be explored. Therefore, the present study has been designed to investigate the effect of Atorvastatin & Pitavastatin on vascular endothelial dysfunction associated memory deficits in rats. In this study L-Methionine induced vascular dementia was assessed by Morris water-maze (MWM) test. Biochemical analysis was also performed to unfold possible mechanism of statins mediated modulation of vascular dementia.

show abstract

Section: Introductionmentioning

confidence: 99%

Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats

et al. 2008

View full text Add to dashboard Cite

show abstract

“…As per the current scenario, only limited cognitive treatment options like the use of Cholinesterase inhibitors and few other therapeutics medicaments were used to minimize dementiarelated cognitive dysfunction symptomatically [3] and memory-related problems to a certain extent. Hence there are lots of potentials to develop therapeutic agents used for the management or prevention of early stages of dementia due to aging and other pathological complications and that kind of drug still need to be explored.…”

Section: Introductionmentioning

confidence: 99%

Influence of Metformin on learning and memory in experimental Amnesia model in Mice

Rajangam¹,

Bhatt²,

Krishnan³

et al. 2020

Ann Alzheimers Dement Care

View full text Add to dashboard Cite

Background: Metformin belongs to the antidiabetic drug but it has been shown some benefi cial effects towards Central Nervous System (CNS) disorders and found to be neuroprotective by inhibiting apoptosis in neuronal cortical cells in various animal models apart from its anti-diabetic potential as per the available reports. Aim and objectives: The present study was aimed to screen the infl uence of Metformin (MET) against experimentally induced amnesia using scopolamine (SCOP) in mice. Materials and methods: Twenty adult albino mice were used for the current study and all the animals were divided into 4 groups of fi ve animals each and treated for about three weeks with MET (10 mg/kg.p.o) whereas amnesia was induced by using SCOP (3 mg/kg ip). The various cognitive skills were assessed by using conventional apparatus like an elevated plus maze (EPM), Morris water maze (MWM), motor coordination by rota rod test and neurotoxicity by chimney test. Results: Results from EPM and MWM indicated the rise in transfer latency and escape latency respectively were due to amnesic effect by administration of SCOP when compared to control animals received normal saline. Administration of standard drug Piracetam (PTM) and test drug MET showed a signifi cant reduction of (p<0.05) in the transfer latency (TL) period were noticed. Thus, the administration of MET signifi cantly ameliorated SCOP-induced amnesia in EPM as indicated by an increase in infl ection ratio and reduction in TL. In the MWM test, MET administration showed a benefi cial reduction of escape latency (EL) period (p<0.05) when compared to SCOP induced amnesia animals. There were no signifi cant changes in motor coordination and no neurotoxic effects were observed as per the results. Conclusion: From the results, the administration of SCOP resulted in signifi cant alterations in the cognitive skills of animals particularly impaired learning and memory skills whereas acute administration of MET for about three weeks, resulted in signifi cant amelioration of scopolamine-induced amnesia. This was noticed as indicated by signifi cant reduction (p<0.05) in transfer latency in the EPM test and signifi cant reduction of (p<0.05) escape latency in the MWM test which refl ects the benefi cial effects of MET against scopolamine-induced memory and behavioral defi cit in mice.

show abstract

Vascular dementia 2003

Cited by 2 publications

References 2 publications

Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats

Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats

Influence of Metformin on learning and memory in experimental Amnesia model in Mice

Contact Info

Product

Resources

About